Related Experiment Video
Updated: Dec 16, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
Kévin Chemello1, Sandra Beeské2, Thi Thu Trang Tran2
1Laboratoire Inserm UMR 1188 DéTROI, Université de La Réunion, Sainte Clotilde, France.
Abstract:
Lipoprotein(a) (Lp[a]) is the most common genetically inherited risk factor for cardiovascular disease. Many aspects of Lp(a) metabolism remain unknown. We assessed the uptake of fluorescent Lp(a) in primary human lymphocytes as well as Lp(a) hepatic capture in a mouse model in which endogenous hepatocytes have been ablated and replaced with human ones. Modulation of LDLR expression with the PCSK9 inhibitor alirocumab did not alter the cellular or the hepatic uptake of Lp(a), demonstrating that the LDL receptor is not a major route for Lp(a) plasma clearance. These results have clinical implications because they underpin why statins are not efficient at reducing Lp(a).
More Related Videos
Related Concept Videos
Receptor-mediated Endocytosis
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Cholesterol: Significance and Regulation
Considering cholesterol and...

